Medical therapy for benign prostatic hyperplasia: Sexual dysfunction and impact on quality of life

International Journal of Impotence Research

Volumn 15, Issue 4, 2003, Pages 299-306

  Carbone Jr , D J ^a   Hodges, S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; Ejaculation; Erectile dysfunction; Quality of life

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; EPHEDRINE; FINASTERIDE; HYDROXYZINE; HYDROXYZINE EMBONATE; IMIPRAMINE; ORCIPRENALINE; ORNADE; PAPAVERINE; PHENTOLAMINE; PHENYLEPHRINE; PLACEBO; PROSTAGLANDIN E1; PSEUDOEPHEDRINE; SALBUTAMOL; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ANIMAL MODEL; ASTHENIA; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; RAT; RETROGRADE EJACULATION; REVIEW; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT OUTCOME; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; COITUS; EJACULATION; HUMANS; LIBIDO; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE 5-ALPHA-REDUCTASE; UROLOGIC DISEASES;

EID: 0041322478     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901017     Document Type: Review

References (73)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
2. Rosen R et al. LUTS and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) [abstract 500161]. American Urological Association Annual Meeting, Orlando, FL, May 26, 2002.
3. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC, the ALGEBI Study Group. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 190-198.
4. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 155-167.
5. Dutkiewics S. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol 2001; 32: 423-432.
6. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
7. Lowe FC. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51.
8. McKiernan JM, Lowe FC. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J 1997; 90: 509-513.
9. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-415.
10. O'Leary MP. LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 2000; 56(Suppl 5A): 7-11.
11. Barry MJ et al, for The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-1557.
12. Schou J, Poulsen AL, Nordling J. The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol 1993; 27: 489-492.
13. Donovan JL et al. The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996; 77: 554-562.
14. Barry MJ et al, Measurement Committee of the American. Urological Association. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33(4 Suppl): AS145-AS155.
15. Lukacs B, Comet D, Grange JC, Thibault P, BPH group in General Practice. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. Br J Urol 1997; 80: 722-730.
16. Epstein RS et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431-1445.
17. Barry MJ, O'Leary MP. Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin N Am 1995; 22: 299-307.
18. Flanigan RC et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-17.
19. Girman CJ et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-831.
20. Garraway WM et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318-321.
21. Tsang KK, Garraway WM. Impact of benign prostatic hyperplasia on general well-being of men. Prostate 1993; 23: 1-7.
22. Sagnier P-P et al. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol 1995; 153: 669-673.
23. Barry MJ et al. Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In: Chatelain C, Denis L, Foo KT, Khoury S, Mc Connell J (eds). Benign Prostatic Hyperplasia, 5th edn. Health Publication Ltd: Bristol, UK, 2001, pp 203-220.
24. Da Silva FC. Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol 1997; 32(Suppl 2): 34-37.
25. Puente JG et al. Relationship between age, lower urinary tract symptoms (LUTS) and various domains of erectile dysfunction (ED) in 1098 patients with BPH in the PREDICT study [abstract 1272]. J Urol 1998; 159: 331.
26. Richard F et al. Results of an epidemiologic surgery carried out with men 50-80 years of age to study urinary disorders, quality of life and sexual function [French]. Prog Urol 2001; 11: 250-263.
27. Schou J, Holm NR, Meyhoff HH. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1996; 179: 119-122.
28. Emberton M et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol 1996; 77: 233-247.
29. Arai Y et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000; 164: 1206-1211.
30. Marberger H. The mechanisms of ejaculation. Basic Life Sci 1974; 4(pt B): 99-110.
31. Master VA, Turek PJ. Ejaculatory physiology and dysfunction. Urol Clin N Am 2001; 28: 363-375.
32. Thomas Jr AJ. Ejaculatory dysfunction. Fertil Steril 1983; 39: 445-454.
33. Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin N Am 1990; 17: 641-649.
34. Walsh PC et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291: 944-949.
35. Rittmaster RS et al. Effect of MK-906, a specific 5 α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989; 10: 259-262.
36. Gormley GJ et al, for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-1191.
37. Moore E et al. Proscar®: five-year experience. Eur Urol 1995; 28: 304-309.
38. 1-Blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials? Eur Urol 2000; 38(Suppl 1): 25-39.
39. 1A-Adrenergic receptors in the isolated human prostate. Pharmacol Commun 1994; 4: 181-188.
40. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993; 22: 301-307.
41. Kaplan SA. Uroselective alpha-blockade for benign prostatic hyperplasia: clinically significant or marketing savvy? Urology 1999; 54: 776-779.
42. Lepor H et al, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-539.
43. Roehrborn CG et al, for the HYCAT Investigator Group. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47: 159-168.
44. Buzelin JM et al. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997; 79: 898-904.
45. Zlotta AR, Schulman CC. BPH and sexuality. Eur Urol 1999; 36(Suppl 1): 107-112.
46. Foglar R et al. Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Clin Pharmacol 1995; 288: 201-207.
47. Kawabe K et al, YM617 Cinical Study Group. Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-911.
48. Giuliano F et al. Tamsulosin has more deleterious effects than alfuzosin on parameters characterizing ejaculation in anesthetized rats [abstract]. In: 97th Annual Meeting of the American Urological Association, Orlando, FL, May 20-25, 2002; and 17th Congress of the European Association of Urology, Birmingham, UK, February 23-26, 2002.
49. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900.
50. Schulman CC et al, on behalf of the European Tamsulosin Study Group. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol 1999; 36: 609-620.
51. Prescribing information: Flomax® (tamsulosin hydrochloride) capsules. Physicians' Desk Reference, 55th edn. Medical Economics Company: Montvale, NJ, 2002, pp 974-977.
52. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-470.
53. Höfner K et al, for the European Tamsulosin Study Group. Tamsulosin 0.4mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335-341.
54. Lukacs B, Leplège A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996; 48: 731-740.
55. Francisca EAE et al. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol 1999; 161: 486-490.
56. 1 adrenergic receptor subtype in RNA expression in human corpus cavernosum [abstract 287]. J Urol. 1993; 149: 285A.
57. Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985; 133: 39-41.
58. 1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin. J Korean Med Sci 1999; 14: 69-74.
59. Kaplan SA et al. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998; 52: 739-743.
60. Sadovsky R. Integrating erectile dysfunction treatment into primary care practice. Am J Med 2000; 109(Suppl 9A): 22S-28S.
61. Paige NM et al. Improvement in emotional well-being and relationships of users of sildenafil. J Urol 2001; 166: 1774-1778.
62. Marberger MJ, on behalf of the Prowess Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. Urology 1998; 51: 677-686.
63. Byrnes CA et al, on behalf of the CUSP Investigators. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. Clin Ther 1995; 17: 956-969.
64. Stoner E, Members of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43: 284-292.
65. Tenover JL et al, on behalf of the Primary Care Investigator Study Group. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther 1997; 19: 243-258.
66. Stoner E, Finasteride Study Group. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. Arch Intern Med 1994; 154: 83-88.
67. Nickel JC et al, for the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). CMAJ 1996; 155: 1251-1259.
68. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-299.
69. Bramson HN et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496-1502.
70. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47: 53-58.
71. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 1998; 64: 636-647.
72. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors. Eur J Pharm Sci 1999; 8: 291-299.
73. Bartlik B, Goldstein MZ. Men's sexual health after midlife. Psychiatr Serv 2001; 52: 291-293, 306.